CARE reaffirms A+ rating to IOL Chemicals and Pharmaceuticals

The 'A+' rating reflects IOL's robust business model, diversified product portfolio

Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program

Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully

Lantern Pharma leverages AI platform to develop breakthrough ADCs with Bielefeld University

Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration

Lonza acquires biotech firm Synaffix

Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology

We need to focus on quality and affordable manufacturing: Mandaviya

Dr. Mandaviya urged the stakeholders to capitalize on the current opportunities

Health Minister Mandaviya inaugurates 8th International Conference on Pharma and Medical Device Sector

Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector

Brain Cells are starved of energy when autophagy malfunctions: New Study

The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments

PI Industries announces twin acquisitions into Pharma API & CDMO space

Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr

Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects

Biocon approves NCD issue

The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.